These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

947 related items for PubMed ID: 18791410

  • 1. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility.
    Hambrock T, Fütterer JJ, Huisman HJ, Hulsbergen-vandeKaa C, van Basten JP, van Oort I, Witjes JA, Barentsz JO.
    Invest Radiol; 2008 Oct; 43(10):686-94. PubMed ID: 18791410
    [Abstract] [Full Text] [Related]

  • 2. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.
    Cirillo S, Petracchini M, Della Monica P, Gallo T, Tartaglia V, Vestita E, Ferrando U, Regge D.
    Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351
    [Abstract] [Full Text] [Related]

  • 3. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies.
    Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, Corvin S, Sievert KD, Claussen CD, Stenzl A, Schlemmer HP.
    Eur Urol; 2006 Oct; 50(4):738-48; discussion 748-9. PubMed ID: 16630688
    [Abstract] [Full Text] [Related]

  • 4. A role of multifactorial evaluation of prostatic 3T MRI in patients with elevated prostatic-specific antigen levels: prospective comparison with ultrasound-guided transrectal biopsy.
    Ferda J, Kastner J, Hora M, Hes O, Fínek J, Topolčan O, Kreuzberg B.
    Anticancer Res; 2013 Jun; 33(6):2791-5. PubMed ID: 23749943
    [Abstract] [Full Text] [Related]

  • 5. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
    Cirillo S, Petracchini M, D'Urso L, Dellamonica P, Illing R, Regge D, Muto G.
    BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
    [Abstract] [Full Text] [Related]

  • 6. 1.5-T magnetic resonance-guided transgluteal biopsies of the prostate in patients with clinically suspected prostate cancer: technique and feasibility.
    Bodelle B, Naguib NN, Schulz B, Eichler K, Müller C, Hansmann ML, Hammerstingl R, Hübner F, Vogl TJ, Zangos S.
    Invest Radiol; 2013 Jun; 48(6):458-63. PubMed ID: 23385402
    [Abstract] [Full Text] [Related]

  • 7. Morphologic, functional, and metabolic magnetic resonance imaging-guided prostate biopsy in a patient with prior negative transrectal ultrasound-guided biopsies and persistently elevated prostate-specific antigen levels.
    Lichy MP, Anastasiadis AG, Aschoff P, Sotlar K, Eschmann SM, Pfannenberg C, Stenzl A, Claussen CD, Schlemmer HP.
    Urology; 2007 Jun; 69(6):1208.e5-8. PubMed ID: 17572221
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings.
    Rouvière O, Valette O, Grivolat S, Colin-Pangaud C, Bouvier R, Chapelon JY, Gelet A, Lyonnet D.
    Urology; 2004 May; 63(5):922-7. PubMed ID: 15134982
    [Abstract] [Full Text] [Related]

  • 10. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
    Goris Gbenou MC, Peltier A, Addla SK, Lemort M, Bollens R, Larsimont D, Roumeguère T, Schulman CC, van Velthoven R.
    Urol Int; 2012 May; 88(1):12-7. PubMed ID: 22004874
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging.
    Miao H, Fukatsu H, Ishigaki T.
    Eur J Radiol; 2007 Feb; 61(2):297-302. PubMed ID: 17085002
    [Abstract] [Full Text] [Related]

  • 15. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.
    Chen M, Dang HD, Wang JY, Zhou C, Li SY, Wang WC, Zhao WF, Yang ZH, Zhong CY, Li GZ.
    Acta Radiol; 2008 Jun; 49(5):602-10. PubMed ID: 18568549
    [Abstract] [Full Text] [Related]

  • 16. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
    Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Ménard C, Warde P, Trachtenberg J, Lockwood G, Milosevic M.
    Int J Radiat Oncol Biol Phys; 2008 Feb 01; 70(2):425-30. PubMed ID: 17881141
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, Kitagaki H, Igawa M.
    Acta Radiol; 2008 Dec 01; 49(10):1207-13. PubMed ID: 19031184
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.